CXCR3, CXCR5, CXCR6, and CXCR7 in Diabetes

Title:CXCR3, CXCR5, CXCR6, and CXCR7 in Diabetes

Volume: 17 Issue: 5

Author(s): Poupak Fallahi, Alda Corrado, Andrea Di Domenicantonio, Giada Frenzilli, Alessandro Antonelli and Silvia Martina Ferrari

Affiliation:

Keywords: CXCL10, CXCR3, CXCR5, CXCR6, CXCR7, T1D.

Abstract: Many studies have suggested that CXCR3, CXCR5, CXCR6 and CXCR7 chemokine receptors are determinant in type 1 diabetes (T1D), expecially in autoimmunity and β-cell destruction. In particular circulating CXCL10 level (the ligand of CXCR3) is high in T1D patients, and this suggests that CXCL10 may be a candidate for a predictive marker of T1D. Blocking the CXCL10/CXCR3 axis in newly onset of diabetes seems to be a potential strategy for the therapy of T1D. Attempts have been done in modulating or blocking CXCR5, CXCR6 and CXCR7 chemokine receptors in experimental settings of T1D. More researches are necessary to evaluate the interplay among cytokines, chemokines and the pathogenesis and therapy of T1D.

Cite this article as:

Fallahi Poupak, Corrado Alda, Di Domenicantonio Andrea, Frenzilli Giada, Antonelli Alessandro and Ferrari Martina Silvia, CXCR3, CXCR5, CXCR6, and CXCR7 in Diabetes, Current Drug Targets 2016; 17 (5) . https://dx.doi.org/10.2174/1389450115666141229153949